DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

DURECT Price Performance

Shares of DRRX stock opened at $0.87 on Monday. The stock has a 50-day moving average of $1.01 and a 200-day moving average of $1.26. DURECT has a one year low of $0.51 and a one year high of $1.88. The stock has a market cap of $27.01 million, a PE ratio of -1.43 and a beta of 0.94.

Hedge Funds Weigh In On DURECT

An institutional investor recently raised its position in DURECT stock. Geode Capital Management LLC raised its stake in DURECT Co. (NASDAQ:DRRX) by 4.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 319,905 shares of the specialty pharmaceutical company’s stock after buying an additional 14,658 shares during the quarter. Geode Capital Management LLC owned about 1.03% of DURECT worth $429,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 28.03% of the company’s stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.